Literature DB >> 11920542

Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis.

Kazuo Tarao1, Yasushi Rino, Shinichi Ohkawa, Setsuo Tamai, Kaoru Miyakawa, Hideki Takakura, Osamu Endo, Michiyasu Yoshitsugu, Norihito Watanabe, Shohei Matsuzaki.   

Abstract

BACKGROUND: Multicentric development of hepatocellular carcinoma (HCC) is a characteristic feature of hepatitis C virus (HCV)-associated cirrhosis (HCV-LC). In this study, the objective was to determine whether the persistent elevation of the serum alanine aminotransferase (ALT) level, which represents the inflammatory necrosis of hepatocytes, is correlated with the multicentric development of hepatocellular carcinoma (HCC) in patients with early-stage HCV-LC.
METHODS: Ninety-three consecutive patients with biopsy proven HCV-LC (Child Stage A) who had been followed for > 5 years for the development of HCC were studied. They were subdivided into three groups according to their serum ALT level: Group A included 33 patients with annual average serum ALT levels that were persistently high (> or = 80 IU; high ALT group), Group B included 41 patients with annual average serum ALT levels that were persistently low (< 80 IU; low ALT group), and Group C included 19 unclassified patients. The patients had been studied prospectively with frequent ultrasonography and magnetic resonance imaging or computed tomography (CT) scans for > 5 years. When the development of HCC was suspected, angiography, infusion of lipiodol into the hepatic artery, and lipiodol-CT scans were performed in all patients to determine the number of HCC nodules.
RESULTS: In Group A, 27 patients (81.8%) developed HCC. Seventeen of 27 patients (63.0%) had multiple nodules. In contrast, in Group B, only 12 patients (29.3%) developed HCC, and only 1 of these 12 patients (8.3%) had multiple nodules. There was a significant difference between Groups A and B in the incidence of developing HCC (P < 0.001) and developing multiple nodules (P = 0.006). In addition, among the male patients, the incidence of developing multiple HCC nodules in Group A (12 of 19 patients; 63.2%) was significantly higher (P < 0.05) compared with the incidence in Group B (0 of 6 patients; 0%). The same tendency was observed among the female patients.
CONCLUSIONS: These results showed a close correlation between multicentric hepatocarcinogenesis and sustained necroinflammation of the liver in patients with HCV-LC. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920542     DOI: 10.1002/cncr.10391

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Baseline characterization of patients aged 70 years and above with hepatocellular carcinoma.

Authors:  Makoto Nakamuta; Shusuke Morizono; Motoyuki Kohjima; Kazuhiro Kotoh; Munechika Enjoji
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

2.  Relation between incidence of hepatic carcinogenesis and integration value of alanine aminotransferase in patients with hepatitis C virus infection.

Authors:  Takashi Kumada; Hidenori Toyoda; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Junji Kondo; Takahiro Yamauchi; Satoshi Nakano
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

3.  A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort.

Authors:  Tian Yang; Jin Zhang; Jun-Hua Lu; Li-Qun Yang; Guang-Shun Yang; Meng-Chao Wu; Wei-Feng Yu
Journal:  J Cancer Res Clin Oncol       Date:  2010-07-06       Impact factor: 4.553

4.  Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.

Authors:  Masakuni Tateyama; Hiroshi Yatsuhashi; Naota Taura; Yasuhide Motoyoshi; Shinya Nagaoka; Kenji Yanagi; Seigo Abiru; Koji Yano; Atsumasa Komori; Kiyoshi Migita; Minoru Nakamura; Hiroyasu Nagahama; Yutaka Sasaki; Yuzo Miyakawa; Hiromi Ishibashi
Journal:  J Gastroenterol       Date:  2010-08-14       Impact factor: 7.527

Review 5.  Does herbal medicine reduce the risk of hepatocellular carcinoma?

Authors:  Yasushi Rino; Norio Yukawa; Naoto Yamamoto
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

6.  Telomerase activity in tumor and remnant liver as predictor of recurrence and survival in hepatocellular carcinoma after resection.

Authors:  Yan-Shen Shan; Yu-Hsiang Hsieh; Pin-Wen Lin
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

7.  Anti-inflammatory drugs reduce the risk of hepatocellular carcinoma development.

Authors:  Yasushi Rino; Kazuo Tarao
Journal:  ISRN Oncol       Date:  2011-07-07

8.  Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients.

Authors:  Kazumi Yamasaki; Masakuni Tateyama; Seigo Abiru; Atsumasa Komori; Shinya Nagaoka; Akira Saeki; Satoru Hashimoto; Ryu Sasaki; Shigemune Bekki; Yuki Kugiyama; Yuri Miyazoe; Atsushi Kuno; Masaaki Korenaga; Akira Togayachi; Makoto Ocho; Masashi Mizokami; Hisashi Narimatsu; Hiroshi Yatsuhashi
Journal:  Hepatology       Date:  2014-10-02       Impact factor: 17.425

9.  Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment.

Authors:  Kazuo Tarao; Akito Nozaki; Takaaki Ikeda; Akira Sato; Hirokazu Komatsu; Tatsuji Komatsu; Masataka Taguri; Katsuaki Tanaka
Journal:  Cancer Med       Date:  2019-02-21       Impact factor: 4.452

10.  Impact of tumor size on hepatectomy outcomes in hepatocellular carcinoma: a nationwide propensity score matching analysis.

Authors:  Suk Kyun Hong; Kwang-Woong Lee; Sola Lee; Su Young Hong; Sanggyun Suh; Eui Soo Han; YoungRok Choi; Nam-Joon Yi; Kyung-Suk Suh
Journal:  Ann Surg Treat Res       Date:  2022-04-05       Impact factor: 1.859

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.